Recalls of Overweight Tablets Reflects Knowledge Gap in Industry on Tablet Making; Solutions Offered
This article was originally published in The Gold Sheet
Executive Summary
The high number of drug product recalls over the past few years for overweight tablets can be attributed to a poor understanding in the pharmaceutical industry on how tablets are made.
You may also be interested in...
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.
US FDA Mulls Advance Notice On Domestic Surveillance Inspections Post-COVID
Criticized for giving foreign sites advance notice of inspections, agency is considering giving such notice to domestic sites too even after surprise inspections become possible.